Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.3600
-0.0014 (-0.39%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Cytosorbents Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 19.1 | 37.06 | 35.6 | 31.08 | 34.69 | 43.17 | |
Revenue Growth | 9.44% | 4.12% | 14.51% | -10.39% | -19.64% | 5.27% |
Cost of Revenue | 10.79 | 10.57 | 10.71 | 9.13 | 13.96 | 11.05 |
Gross Profit | 26.41 | 26.49 | 24.89 | 21.95 | 20.73 | 32.12 |
Selling, General & Admin | 35.36 | 35.65 | 33.73 | 38.31 | 37.14 | 38.48 |
Research & Development | 4.45 | 5.09 | 7.61 | 15.59 | 15.12 | 16.38 |
Other Operating Expenses | - | 0.51 | - | - | - | - |
Total Operating Expenses | 39.81 | 41.24 | 41.34 | 53.9 | 52.25 | 54.86 |
Operating Income | -13.91 | -14.75 | -16.45 | -31.95 | -31.52 | -22.74 |
Interest Expense | -2.86 | -2.61 | -1.4 | -0.16 | 0.13 | 0.03 |
Other Non-Operating Income (Expense) | 5.08 | 8.76 | -4.56 | 2.05 | -2.52 | -2.58 |
Total Non-Operating Income (Expense) | 2.22 | 6.15 | -5.96 | 1.89 | -2.38 | -2.55 |
Pretax Income | -11.69 | -8.6 | -22.41 | -30.06 | -33.91 | -25.29 |
Provision for Income Taxes | - | -0.4 | -1.69 | -0.81 | -1.09 | -0.74 |
Net Income | -11.69 | -8.2 | -20.72 | -29.25 | -32.81 | -24.56 |
Net Income to Common | 1.95 | -8.2 | -20.72 | -29.25 | -32.81 | -24.56 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 63 | 62 | 54 | 45 | 44 | 43 |
Shares Outstanding (Diluted) | 64 | 62 | 54 | 45 | 44 | 43 |
Shares Change | 13.94% | 14.32% | 21.90% | 2.49% | 0.49% | 11.70% |
EPS (Basic) | -0.19 | -0.13 | -0.38 | -0.65 | -0.75 | -0.57 |
EPS (Diluted) | -0.19 | -0.13 | -0.38 | -0.65 | -0.75 | -0.57 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -10.25 | -12.54 | -14.71 | -22.19 | -34.32 | -17.65 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.16 | -0.20 | -0.27 | -0.50 | -0.79 | -0.41 |
Gross Margin | 138.28% | 71.48% | 69.92% | 70.62% | 59.77% | 74.41% |
Operating Margin | -72.80% | -39.79% | -46.22% | -102.78% | -90.87% | -52.69% |
Profit Margin | -61.20% | -22.12% | -58.21% | -94.09% | -94.59% | -56.89% |
FCF Margin | -53.64% | -33.84% | -41.33% | -71.40% | -98.94% | -40.88% |
EBITDA | -13.49 | -13.12 | -14.71 | -29.93 | -30.39 | -21.62 |
EBITDA Margin | -70.63% | -35.39% | -41.32% | -96.27% | -87.61% | -50.08% |
EBIT | -13.91 | -14.75 | -16.45 | -31.95 | -31.52 | -22.74 |
EBIT Margin | -72.80% | -39.79% | -46.22% | -102.78% | -90.87% | -52.69% |
Effective Tax Rate | - | 4.66% | 7.55% | 2.71% | 3.22% | 2.91% |